Company registration number 05834626 (England and Wales)
Q BIOTECHNOLOGIES LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024
PAGES FOR FILING WITH REGISTRAR
Q BIOTECHNOLOGIES LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
Q BIOTECHNOLOGIES LTD
BALANCE SHEET
AS AT
29 FEBRUARY 2024
29 February 2024
- 1 -
29 February 2024
28 February 2023
Notes
£
£
£
£
Current assets
Debtors
3
291,426
309,198
Cash at bank and in hand
2,643
3,604
294,069
312,802
Creditors: amounts falling due within one year
4
(178,114)
(191,513)
Net current assets
115,955
121,289
Capital and reserves
Called up share capital
5
100
100
Profit and loss reserves
115,855
121,189
Total equity
115,955
121,289

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 29 February 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 29 November 2024
Mr C M Pillans
Director
Company registration number 05834626 (England and Wales)
Q BIOTECHNOLOGIES LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 FEBRUARY 2024
- 2 -
1
Accounting policies
Company information

Q Biotechnologies Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Unit 1A Summerlands Trading Estate, Endmoor, Kendal, LA8 0FB. The main place of business is University of Lincoln, Rope Walk, Lincoln, LN6 7DQ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

At the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company is reliant on the financial support of its fellow subsidiary company, Q Medical Technologies Limited, to remain a going concern. Due to supply issues in 2023, a product which the company usually sells remains currently unavailable for resale, potentially impacting on future profitability and cash flow. As a consequence, management have undertaken a restructuring including cost saving exercise and Q Medical Technologies Limited has now recently returned to profitability since the year-end. The director of Q Medical Technologies Limited has assessed the impact on the company of the above, including preparing detailed forecasts, and does not consider this creates a material uncertainty at this time and has therefore concluded that the going concern basis remains appropriate as there is a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus, the director continues to adopt the going concern basis of accounting in preparing the financial statements.true

1.3
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.4
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

1.5
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Q BIOTECHNOLOGIES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 29 FEBRUARY 2024
1
Accounting policies
(Continued)
- 3 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
1
1
3
Debtors
2024
2023
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
291,426
291,426
Other debtors
-
5,335
291,426
296,761
4
Creditors: amounts falling due within one year
2024
2023
£
£
Amounts due to group undertakings
14,447
26,671
Other creditors
163,667
164,842
178,114
191,513
Q BIOTECHNOLOGIES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 29 FEBRUARY 2024
- 4 -
5
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary of £1 each
100
100
100
100
6
Related party transactions

The company is a wholly owned subsidiary of Pillans Group Limited and in accordance with paragraph 33.1A is therefore not required to disclose transactions and balances with that company and its fellow subsidiary Q Medical Technologies Limited.

2024-02-292023-03-01false29 November 2024CCH SoftwareCCH Accounts Production 2024.200No description of principal activityMr C M Pillansfalsefalse058346262023-03-012024-02-29058346262024-02-29058346262023-02-2805834626core:CurrentFinancialInstrumentscore:WithinOneYear2024-02-2905834626core:CurrentFinancialInstrumentscore:WithinOneYear2023-02-2805834626core:CurrentFinancialInstruments2024-02-2905834626core:CurrentFinancialInstruments2023-02-2805834626core:ShareCapital2024-02-2905834626core:ShareCapital2023-02-2805834626core:RetainedEarningsAccumulatedLosses2024-02-2905834626core:RetainedEarningsAccumulatedLosses2023-02-2805834626bus:Director12023-03-012024-02-29058346262022-03-012023-02-2805834626bus:PrivateLimitedCompanyLtd2023-03-012024-02-2905834626bus:SmallCompaniesRegimeForAccounts2023-03-012024-02-2905834626bus:FRS1022023-03-012024-02-2905834626bus:AuditExemptWithAccountantsReport2023-03-012024-02-2905834626bus:FullAccounts2023-03-012024-02-29xbrli:purexbrli:sharesiso4217:GBP